220603-04-3

Basic information

• Product Name: (2-chloro-4-fluorophenyl)-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone
• Synonyms: (2-chloro-4-fluorophenyl)-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone
• CAS NO: 220603-04-3
• Molecular Weight: 353.783
• Mol File: 220603-04-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2-chloro-4-fluorophenyl)-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2-chloro-4-fluorophenyl)-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone(220603-04-3)
• EPA Substance Registry System: (2-chloro-4-fluorophenyl)-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone(220603-04-3)

Safety Data

• Hazardous Substances Data: 220603-04-3(Hazardous Substances Data)

Upstream product

• 21900-54-9 2-chloro-4-fluorobenzoyl chloride 
• 16287-36-8 6,11-dihydro-5H-pyrido{2,3-b][1,5]benzodiazepine 
• 10189-78-3 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one 
• 95-54-5 1,2-diamino-benzene 
• 10177-29-4 4-chloronicotinic acid 
• 2252-51-9 2-choro-4-fluorobenzoic acid 
• 2942-59-8 2-chloronicotinic acid 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 220602-88-0 {2-Chloro-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 
• 875414-12-3 [2-chloro-4-(5-trifluoromethyl-pyrazol-1-yl)-phenyl]-(5,11-dihydro-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)-methanone 
• 220602-55-1 [2-chloro-4-(3-methyl-1H-pyrazol-1-yl)-phenyl]-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 
• 220602-58-4 [2-Chloro-4-(5-methyl-1H-pyrazol-1-yl)-phenyl]-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 

Relevant articles and documents

Pyridobenzodiazepines: A novel class of orally active, vasopressin V 2 receptor selective agonists

Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.

Tricyclic pyrido vasopressin agonists

The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

Tricyclic vasopressin agonists

The present invention provides compounds of the general formula: wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.